Your browser doesn't support javascript.
loading
Rare complications of multikinase inhibitor treatment
Pitoia, Fabián; Schmidt, Angélica; Bueno, Fernanda; Abelleira, Erika; Jerkovich, Fernando.
  • Pitoia, Fabián; University of Buenos Aires. Division of Endocrinology. Buenos Aires. AR
  • Schmidt, Angélica; University of Buenos Aires. Division of Endocrinology. Buenos Aires. AR
  • Bueno, Fernanda; University of Buenos Aires. Division of Endocrinology. Buenos Aires. AR
  • Abelleira, Erika; University of Buenos Aires. Division of Endocrinology. Buenos Aires. AR
  • Jerkovich, Fernando; University of Buenos Aires. Division of Endocrinology. Buenos Aires. AR
Arch. endocrinol. metab. (Online) ; 62(6): 636-640, Dec. 2018. tab, graf
Article in English | LILACS | ID: biblio-983805
ABSTRACT
ABSTRACT

Objective:

The advent of multikinase inhibitor (MKI) therapy has led to a radical change in the treatment of patients with advanced thyroid carcinoma. The aim of this manuscript is to communicate rare adverse events that occurred in less than 5% of patients in clinical trials in a subset of patients treated in our hospital. Subjects and

methods:

Out of 760 patients with thyroid cancer followed up with in our Division of Endocrinology, 29 (3.8%) received treatment with MKIs. The median age at diagnosis of these patients was 53 years (range 20-70), and 75.9% of them were women. Sorafenib was prescribed as first-line treatment to 23 patients with differentiated thyroid cancer and as second-line treatment to one patient with advanced medullary thyroid cancer (MTC). Vandetanib was indicated as first-line treatment in 6 patients with MTC and lenvatinib as second-line treatment in two patients with progressive disease under sorafenib treatment.

Results:

During the follow-up of treatment (mean 13.7 ± 7 months, median 12 months, range 6-32), 5/29 (17.2%) patients presented rare adverse events. These rare adverse effects were heart failure, thrombocytopenia, and squamous cell carcinoma during sorafenib therapy and squamous cell carcinoma and oophoritis with intestinal perforation during vandetanib treatment.

Conclusions:

About 3 to 5 years after the approval of MKI therapy, we learned that MKIs usually lead to adverse effects in the majority of patients. Although most of them are manageable, we still need to be aware of potentially serious and rare or unreported adverse effects that can be life-threatening.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Piperidines / Quinazolines / Carcinoma / Carcinoma, Medullary / Protein Kinase Inhibitors / Antineoplastic Agents Type of study: Etiology study / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male Language: English Journal: Arch. endocrinol. metab. (Online) Journal subject: Endocrinology / Metabolism Year: 2018 Type: Article Affiliation country: Argentina Institution/Affiliation country: University of Buenos Aires/AR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Piperidines / Quinazolines / Carcinoma / Carcinoma, Medullary / Protein Kinase Inhibitors / Antineoplastic Agents Type of study: Etiology study / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male Language: English Journal: Arch. endocrinol. metab. (Online) Journal subject: Endocrinology / Metabolism Year: 2018 Type: Article Affiliation country: Argentina Institution/Affiliation country: University of Buenos Aires/AR